Participate in Research at CU Anschutz

An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

Study IMVT-1401-3203 is a 2-cohort extension study for eligible participants completing the Week 24 visit on the feeder studies, IMVT-1401-3201 or IMVT-1401-3202. Participants will be assessed as proptosis responders or non-responders at Week 24 in the feeder studies. Based upon this assessment, participants will be assigned as follows: - An Observational Cohort, comprised of participants classified as proptosis responders in either IMVT-1401-3201 or IMVT-1401-3202, who will enter a 24- week non-treatment observational study during which the durability of their proptosis response will be assessed. - A Treatment Cohort, comprised of participants classified as proptosis non responders in either IMVT-1401-3201 or IMVT-1401-3202, who will enter an open-label, non-placebo-controlled study of batoclimab as an initial or extended treatment of batoclimab of 680 mg subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks.